A potential target associated with both cancer and cancer stem cells: A combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes

Journal of Controlled Release

Volumn 129, Issue 1, 2008, Pages 18-25

  Liu, Yang ^a   Lu, Wan Liang ^a   Guo, Jia ^a   Du, Ju ^a   Li, Ting ^a   Wu, Jin Wei ^a   Wang, Gui Ling ^a   Wang, Jian Cheng ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Breast cancer; Cancer stem cells; Parthenolide stealthy liposomes; Side population; Vinorelbine stealthy liposomes

Indexed keywords

BIOACTIVITY; BIOLOGICAL ORGANS; CELL DEATH; CYTOTOXICITY; ENZYME INHIBITION; POPULATION DYNAMICS;

BREAST CANCER; CANCER STEM CELLS; PARTHENOLIDE STEALTHY LIPOSOMES; SIDE POPULATION; VINORELBINE STEALTHY LIPOSOMES;

TUMORS;

LIPOSOME; NAVELBINE; PARTHENOLIDE; PARTHENOLIDE STEALTHY LIPOSOME; VINORELBINE DITARTRATE; VINORELBINE STEALTHY LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER STEM CELL; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; FEMALE; HUMANS; LIPIDS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; SESQUITERPENES; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 44649133215     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.03.022     Document Type: Article

References (33)

1. Vargo-Gogola T., and Rosen J.M. Modeling breast cancer: one size does not fit all. Nat. Rev., Cancer 7 9 (2007) 659-672
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18 3 (2007) 581-592
3. Zhang M., and Rosen J.M. Stem cells in the etiology and treatment of cancer. Curr. Opin. Genet. Dev. 16 1 (2006) 60-64
4. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistant. Nat. Rev., Cancer 5 4 (2005) 275-284
5. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., and Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7 9 (2001) 1028-1034
6. Donnenberg V.S., Landreneau R.J., and Donnenberg A.D. Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J. Control. Release 122 3 (2007) 385-391
7. Kondo T., Setoguchi T., and Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. U.S.A. 101 3 (2004) 781-786
8. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., Goodell M.A., and Brenner M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U.S.A. 101 39 (2004) 14228-14233
9. Haraguchi N., Utsunomiya T., Inoue H., Tanaka F., Mimori K., Barnard G.F., and Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24 3 (2006) 506-513
10. Wang J., Guo L.P., Chen L.Z., Zeng Y.X., and Lu S.H. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 67 8 (2007) 3716-3724
11. Sano M., Tokuda Y., Noguchi S., Aogi K., Saeki T., Tabei T., Hatake K., and Fujii H. A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer. Gan To Kagaku Ryoho 33 8 (2006) 1091-1097 Japanese
12. Kellokumpu-Lehtinen P.L., Sunela K., Lehtinen I., Joensuu H., and Sjostrom-Mattson J. Finnish Breast Cancer Group. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin. Breast Cancer 7 5 (2006) 401-405
13. Catania C., Medici M., Magni E., Munzone E., Cardinale D., Adamoli L., Sanna G., Minchella I., Radice D., Goldhirsch A., and Nole F. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann. Oncol. 18 12 (2007) 1969-1975
14. Douillard J.Y., Laporte S., Fossella F., Georgoulias V., Pujol J.L., Kubota K., Monnier A., Kudoh S., Rubio J.E., and Cucherat M. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J. Thorac. Oncol. 2 10 (2007) 939-946
15. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., Pfeifer W., O'Byrne K.J., Welte T., Kolb R., Pirker R., Chemaissani A., Perol M., Ranson M.R., Ellis P.A., Pilz K., and Reck M. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19 2 (2008) 362-369
16. Gridelli C., Maione P., Illiano A., Piantedosi F.V., Favaretto A., Bearz A., Robbiati S.F., Filipazzi V., Lorusso V., Carrozza F., Iaffaioli R.V., Manzione L., Gallo C., Morabito A., and Perrone F. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J. Clin. Oncol. 25 29 (2007) 4663-4669
17. Mano M. Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. Cancer Treat. Rev. 32 2 (2006) 106-118
18. Guzman M.L., Rossi R.M., Karnischky L., Li X., Peterson D.R., Howard D.S., and Jordan C.T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105 11 (2005) 4163-4169
19. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 12 Pt 1 (1986) 6387-6392
20. Li X., Ruan G.R., Lu W.L., Hong H.Y., Liang G.W., Zhang Y.T., Liu Y., Long C., Ma X., Yuan L., Wang J.C., Zhang X., and Zhang Q. A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J. Control. Release 112 2 (2006) 186-198
21. Zhigaltsev I.V., Maurer N., Edwards K., Karlsson G., and Cullis P.R. Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J. Control. Release 110 2 (2006) 378-386
22. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100 7 (2003) 3983-3988
23. Menéndez J.A., Ropero S., del Barbacid M.M., Montero S., Solanas M., Escrich E., Cortés-Funes H., and Colomer R. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res. Treat. 72 3 (2002) 203-219
24. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., Dinulescu D.M., Connolly D., Foster R., Dombkowski D., Preffer F., Maclaughlin D.T., and Donahoe P.K. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl. Acad. Sci. U.S.A. 103 30 (2006) 11154-11159
25. Foster P.A., Newman S.P., Chander S.K., Stengel C., Jhalli R., Woo L.L., Potter B.V., Reed M.J., and Purohit A. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin. Cancer Res. 12 18 (2006) 5543-5549
26. Mamot C., Drummond D.C., Noble C.O., Kallab V., Guo Z., Hong K., Kirpotin D.B., and Park J.W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 65 24 (2005) 11631-11638
27. Guzman M.L., Rossi R.M., Neelakantan S., Li X., Corbett C.A., Hassane D.C., Becker M.W., Bennett J.M., Sullivan E., Lachowicz J.L., Vaughan A., Sweeney C.J., Matthews W., Carroll M., Liesveld J.L., Crooks P.A., and Jordan C.T. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110 13 (2007) 4427-4435
28. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 17 (1995) 3752-3756
29. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., Richardson A., and Weinberg R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. U.S.A. 101 14 (2004) 4966-4971
30. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M.A., and Daidone M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65 13 (2005) 5506-5511
31. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J., Claypool K., and Tang D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 65 14 (2005) 6207-6219
32. Rosen P.P., Groshen S., Saigo P.E., Kinne D.W., and Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J. Clin. Oncol. 7 9 (1989) 1239-1251
33. Ragaz J., Olivotto I.A., Spinelli J.J., Phillips N., Jackson S.M., Wilson K.S., Knowling M.A., Coppin C.M., Weir L., Gelmon K., Le N., Durand R., Coldman A.J., and Manji M. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J. Natl. Cancer Inst. 97 2 (2005) 116-126